INTRODUCTION {#sec1-1}
============

Hirsutism is defined as excess growth of terminal hair in females, distributed in an androgen-dependent pattern.\[[@ref1]\] It is present in approximately 7% of women, and can lead to severe implications on their quality of life.\[[@ref2]\] While several causes have been implicated in hirsutism development, androgenic factors are the most prevalent, accounting for more than 80% of the cases,\[[@ref3]\] and polycystic ovary syndrome is the most common sole disorder for hirsutism.\[[@ref4]\] Iatrogenic causes for hirsutism, including medications, are considered as an uncommon cause, although the exact incidence is not well defined.\[[@ref5]\] We present a case of severe hirsutism developing after treatment with isotretinoin, a widely prescribed drug in dermatology practice.

CASE REPORT {#sec1-2}
===========

A 48-year-old female presented with the severe pustular eruption of 1-month duration. Her past medical history included thymoma that was treated with irradiation 10 years prior to her current consultation. She was otherwise healthy and did not take any medications. Physical examination revealed the presence of numerous facial erythematous nodules and pustules. The patient was diagnosed with papulopustular rosacea, and treatment was initiated with isotretinoin 20 mg daily for 1-month. Following good clinical response and lack of side-effects, the dose was increased to 30 mg daily. Two months later, the patient developed excess hair growth on her face, located mainly to the temples and the forehead. The patient denied other symptoms of virilization, including change of voice or growth of hair in other locations. Androgen levels (including testosterone, dehydroepiandrosterone sulfate and Δ--4 androstenedione) were within the normal limits. Physical examination revealed the presence of coarse black hairs on her bilateral temples and sides of the forehead \[[Figure 1](#F1){ref-type="fig"}\].

![Coarse black hair on the temples (a) and side of the forehead (b) in a patient treated with isotretinoin for rosacea](IJT-7-129-g001){#F1}

DISCUSSION {#sec1-3}
==========

Isotretinoin is a widely prescribed medication in dermatology practice, mainly for the treatment of severe nodulocystic acne. While hirsutism is considered to be one of the possible side effects of isotretinoin therapy, its exact frequency is not defined.\[[@ref6]\] To the best of our knowledge, only one case has been reported before,\[[@ref7]\] and such occurrence has not been reported in the dermatology literature. Our patient did not show additional features of hyperandrogenism, and a recent study also demonstrated that isotretinoin therapy does not seem to alter androgen levels in acne patients.\[[@ref8]\] Therefore, the exact mechanism for hirsutism following isotretinoin treatment is still obscure.

Interestingly, the distribution of excess facial hair is reminiscent of the distribution of hirsutism seen in females following the topical application of minoxidil as a treatment for androgenetic alopecia. Furthermore in these cases, the most common sites for excessive hair growth are the forehead and sideburns.\[[@ref9]\]

Although our patient experienced severe facial hirsutism, this manifestation can often be transient. An additional patient that was observed by us, a 22-year-old female patient who was treated with isotretinoin for cystic acne, also developed facial hirsutism on her forehead, chin, and cheeks \[[Figure 2a](#F2){ref-type="fig"}\]. In this case, facial hirsutism resolved spontaneously several months after cessation of isotretinoin treatment \[[Figure 2b](#F2){ref-type="fig"}\]. Isotretinoin is one of the major components in the anti-acne armamentarium. Knowledge of its possible adverse effects is of major importance for the treating dermatologist.\[[@ref10]\]

![Facial hirsutism in a 22-year-old female patient treated with isotretinoin for cystic acne (a), that resolved spontaneously several months after cessation of treatment (b)](IJT-7-129-g002){#F2}
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